Medication Study for those with Relapsing Multiple Sclerosis (Ages 18-55)
Official Title
AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Purpose
The purpose of this study is to determine exactly how the drug Ocrelizumab interacts with human cells to produce its intended effect in those with Relapsing Multiple Sclerosis (RMS).
Could this study be right for you?
You may be eligible for this study if you:
- Have been diagnosed with Relapsing Multiple Sclerosis
- Have an EDSS score of 0-5.5, inclusive, at screening, and a disease duration less than 15 years if EDSS > 5.0
- Are either treatment-naïve or receiving treatment with disease-modifying therapies
- Have had at least one clinically documented relapse in the past year and/or at least one T1-weighted Gd-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment